CHRS compared with KLRS: revenue, margins and what each company keeps, and the suppliers and customers both name

CHRSCoherus Oncology, Inc.

Mkt capRevenueRevenue

KLRSKalaris Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

CHRSCoherus Oncology, Inc.

KLRSKalaris Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

rebased to 0%

CHRS, solidKLRS, dashed

Supply-chain overlap

Revenue flow

CHRS: latest quarter is a loss; flow not drawable. KLRS: latest quarter not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only CHRS 8

GSKGlaxoSmithKlinesupplier

INOInovio Pharmaceuticalscustomer

—Junshi Biosciencesunlistedsupplier

—Janssen Research & Developmentunlistedsupplier

4 more · CHRS chain ›

Shared 0

No disclosed counterparties: KLRS.

Only KLRS 0

None

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

CHRSCoherus Oncology, Inc.

0.87▼−2.68%· post 0.83

Mkt cap$128.3MRevenue$14MQ2 FY26Revenue$42MFY25

KLRSKalaris Therapeutics, Inc.

2.00▼−6.10%· post 2.04

ClosedOct 30 '26

Mkt cap$48.3MRevenue—Revenue—

Compare

ClosedOct 30 '26

CHRSCoherus Oncology, Inc.

KLRSKalaris Therapeutics, Inc.

0.87▼−2.68%post 0.83

Price

2.00▼−6.10%post 2.04

$128.3M

Mkt cap

$48.3M

Q2 FY26$14M

Revenue

—

FY25$42M

Revenue

—

CHRS0.87▼−2.68%vsKLRS2.00▼−6.10%ClosedOct 30 '26